ストックスクリーナーアプリを入手
4.26
7.30%
0.29
アフターアワーズ：
4.20
-0.06
-1.41%
前日終値:
$3.97
開ける：
$4.23
24時間の取引高:
373.88K
Relative Volume:
0.25
時価総額：
$423.14M
収益：
$58.36M
当期純損益:
$-25.72M
株価収益率:
-11.70
EPS:
-0.3641
ネットキャッシュフロー:
$-24.91M
1週間 パフォーマンス:
+5.71%
1か月 パフォーマンス:
+29.48%
6か月 パフォーマンス:
+36.10%
1年 パフォーマンス:
+27.93%
1日の値動き範囲:
$4.22
$4.30
1週間の範囲:
$3.955
$4.50
52週間の値動き範囲:
$2.12
$5.80
Aquestive Therapeutics Inc Stock (AQST) Company Profile
名前
Aquestive Therapeutics Inc
セクター
電話
908-941-1900
住所
30 TECHNOLOGY DRIVE, WARREN, NJ
AQST を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AQST
Aquestive Therapeutics Inc
|
4.26 | 394.33M | 58.36M | -25.72M | -24.91M | -0.3641 |
|
ZTS
Zoetis Inc
|
153.45 | 67.31B | 9.29B | 2.52B | 2.28B | 5.57 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.74 | 45.95B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
HLN
Haleon Plc Adr
|
9.75 | 43.35B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.58 | 18.68B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
305.61 | 13.44B | 2.99B | 1.21B | 1.13B | 25.06 |
Aquestive Therapeutics Inc Stock (AQST) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-06-02 | 再開されました | Oppenheimer | Outperform |
| 2024-12-17 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-05-10 | 開始されました | Leerink Partners | Outperform |
| 2024-04-11 | 開始されました | Piper Sandler | Overweight |
| 2024-03-28 | 開始されました | Raymond James | Outperform |
| 2021-04-07 | 再開されました | RBC Capital Mkts | Outperform |
| 2019-04-22 | 開始されました | H.C. Wainwright | Buy |
| 2019-01-03 | 開始されました | Lake Street | Buy |
| 2018-08-20 | 開始されました | JMP Securities | Mkt Outperform |
| 2018-08-20 | 開始されました | RBC Capital Mkts | Outperform |
すべてを表示
Aquestive Therapeutics Inc (AQST) 最新ニュース
What drives Aquestive Therapeutics Inc. stock priceFree Capital Allocation Plans - Autocar Professional
Aquestive Therapeutics Inc. Stock Analysis and ForecastFree Wealth Planning Blueprint - jammulinksnews.com
Is Aquestive Therapeutics Inc. a good long term investmentRobust financial gains - Autocar Professional
What analysts say about Aquestive Therapeutics Inc. stockAccelerated profit realization - jammulinksnews.com
Aquestive Therapeutics Names Sherry Korczynski as Chief Commercial Officer - GlobeNewswire
EpiPen Veteran to Lead Aquestive's Revolutionary Oral Epinephrine Launch as New Chief Commercial Officer - Stock Titan
After Leaping 29% Aquestive Therapeutics, Inc. (NASDAQ:AQST) Shares Are Not Flying Under The Radar - simplywall.st
Aquestive's Anaphylm to be reviewed by Health Canada - MSN
When is the best time to buy Aquestive Therapeutics Inc. stockAlpha Stock Ideas - Newser
Will Aquestive Therapeutics Inc. stock benefit from AI tech trendsFree Professional Portfolio Management - Newser
Why Aquestive Therapeutics Inc. stock attracts strong analyst attentionSteady Income Ideas - beatles.ru
Cantor Equity Partners I, Inc. shares rise 2.24% premarket after Aquestive Therapeutics' positive drug submission meeting with Health Canada. - AInvest
11,303 Shares in Aquestive Therapeutics, Inc. (NASDAQ:AQST) Acquired by Cambridge Investment Research Advisors Inc. - Defense World
Aquestive Therapeutics Provides International Expansion Update for Anaphylm™ (epinephrine) Sublingual Film - GlobeNewswire
What makes Aquestive Therapeutics Inc. stock price move sharplyFree High-Profit Stock Picks - Newser
Aquestive's Anaphylm to be reviewed by Health Canada (AQST) - Seeking Alpha
Aquestive schedules regulatory meetings for epinephrine film in Canada, EU - Investing.com Canada
How Aquestive Therapeutics Inc. stock performs during market volatilityDaily Stock Radar - Newser
Aquestive Therapeutics Says Canadian Regulator Has Granted Meeting to Discuss Anaphylm Approval - MarketScreener
Aquestive schedules regulatory meetings for epinephrine film in Canada, EU By Investing.com - Investing.com Nigeria
Aquestive Therapeutics Inc (AQST) 財務データ
収益
当期純利益
現金流量
EPS
1.34%
大文字化:
|
ボリューム (24 時間):